Institute for Clinical and Economic Review Announces Departure of Dan Ollendorf; Launches Search for New Chief Scientific Officer

Boston – July 3, 2018 – The Institute for Clinical and Economic Review (ICER) announced today that Chief Scientific Officer Dan Ollendorf, PhD, will be leaving to take up a position at the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center, where he will serve as CEVR’s Director of Value Assessment and Global Health Initiatives. ICER has launched a nationwide search for a new Chief Scientific Officer, and Dr. Ollendorf will remain at ICER through September to ensure a smooth transition.

“Dan has been an extraordinary colleague and has been an integral part of every step of ICER’s evolution since we first launched over 10 years ago,” said Steve Pearson, MD, MSc, ICER’s President. “His leadership and wise counsel within ICER will be dearly missed. But everyone understands the call to new challenges, and the entire ICER community wishes him the very best as he applies his expertise in a new leadership role.”

“We are seeking a new Chief Scientific Officer to join ICER and take up an unrivaled opportunity to help the US address the core challenge of sustaining innovation while transitioning to a health care system in which every patient can be guaranteed access to high-value care.”

The Chief Scientific Officer job description and list of professional qualifications is available on ICER’s website. Interested candidates are encouraged to submit a cover letter and resume to careers@icer-review.org.


About ICER
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.